{"id":16306,"date":"2022-01-18T12:33:26","date_gmt":"2022-01-18T12:33:26","guid":{"rendered":"https:\/\/clinlabint.com\/?p=16306"},"modified":"2022-01-20T12:33:16","modified_gmt":"2022-01-20T12:33:16","slug":"gennext-technologies-awarded-second-us-patent-for-protein-footprinting","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/gennext-technologies-awarded-second-us-patent-for-protein-footprinting\/","title":{"rendered":"GenNext Technologies awarded second US patent for protein footprinting"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

GenNext Technologies awarded second US patent for protein footprinting<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

GenNext Technologies, a growth-stage company providing instrumentation, software, and services, has earned a second patent protecting the company\u2019s novel radical dosimetry technology which vastly improves the utility of protein footprinting for the study of biopharma-ceutical structure, function, and safety.<\/h3>\n

<\/p>\n

The United States Patent and Trademark Office issued the \u2018Radical Dosimetry for the Analysis of Biopharmaceuticals and Biological Molecules\u2019 patent, which protects the company\u2019s novel core technology and Intellectual Property that enables real-time assessment of protein footprinting chemical reactions with robust accuracy and reproduci-bility, while substantially improving ease-of-use. Specifically, this patent protects GenNext\u2019s novel approach to determining protein tertiary and quaternary structure, along with associated conformation, of a given biomolecule. This insight enables researchers to develop superior biosimilars and biotherapeutics that limit or eliminate adverse drug reactions while increasing the drug\u2019s efficacy.<\/p>\n

GenNext says their mission is to help researchers elucidate, through protein footprinting, the critical role that Higher Order Structure (HOS) plays in the safety, stability, and function of biotherapeutics. Although protein footprinting promised to revolutionize drug discovery, adoption has been slow due to the inherent complexity, dangerous instrumentation, and reproducibility challenges of older methods.<\/p>\n

\u201cWith the launch of our Flash Oxidation System and Services in 2019, we solved these adoption problems by increasing the sensitivity, reproducibility, and ease-of-use of protein footprinting,\u201d said Scot R. Weinberger, Founder and CEO of GenNext. \u201cNow that a full-solution HOS technology platform and service is available to the structural biology research community, we\u2019ve seen a surging adoption of this powerful technique by leading US and EU biopharmaceutical companies. We\u2019re delighted to receive our second US patent as validation of our leadership in commercializing novel and robust protein footprinting technology.\u201d<\/p>\n<\/div><\/section>
\n

<\/div>

GenNext\u2019s Flash Oxidation System<\/p>\n<\/div><\/div><\/div>\"\"<\/div><\/div><\/div>
\n